Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$9.77
$0.49
$2.60
$2.35B1.5539,610 shs3.45 million shs
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$38.22
$38.12
$19.06
$40.14
$2.99B0.81.34 million shsN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$12.48
-3.4%
$14.84
$8.08
$37.75
$264.08M0.47254,185 shs79,696 shs
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$8.11
-5.1%
$10.59
$6.01
$13.14
$603.36M1.14553,343 shs426,623 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00%0.00%0.00%0.00%+1.87%
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.41%-5.67%-21.76%+2.04%-63.88%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-5.15%-6.46%-22.54%-22.02%-7.21%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.635 of 5 stars
3.10.00.04.72.82.50.6
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.2024 of 5 stars
3.00.00.00.01.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.17
Hold$19.3354.91% Upside
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.00
Hold$15.0084.96% Upside

Current Analyst Ratings

Latest ENTA, TPTX, BLUSF, DRNA, and ZYME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/8/2024
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$12.00 ➝ $11.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$30K0.00N/AN/A$0.25 per share0.00
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$164.31M18.17N/AN/A$1.84 per share20.77
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$79.20M3.33N/AN/A$10.29 per share1.21
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
Zymeworks Inc. stock logo
ZYME
Zymeworks
$76.01M7.53N/AN/A$6.63 per share1.22

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$133.82M-$6.56N/AN/AN/A-187.77%-60.38%-32.29%5/13/2024 (Estimated)
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.74N/AN/AN/A-156.12%-26.20%-20.29%5/2/2024 (Confirmed)

Latest ENTA, TPTX, BLUSF, DRNA, and ZYME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.31N/A+$0.31N/AN/AN/A  
3/6/2024Q4 2023
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.39-$0.20+$0.19-$0.20$18.32 million$16.93 million
2/7/2024Q1 2024
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.18-$1.58-$0.40-$1.58$22.74 million$18.00 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
13.87
13.87
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/A
2.46
2.46
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
6.25
6.25
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
7.41
7.41

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
10159.12 millionN/ANot Optionable
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
30278.13 million70.16 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
14521.16 million18.27 millionOptionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
27270.57 million69.71 millionOptionable

ENTA, TPTX, BLUSF, DRNA, and ZYME Headlines

SourceHeadline
3 Top Stocks to Invest in for Amazing Earnings Acceleration3 Top Stocks to Invest in for Amazing Earnings Acceleration
zacks.com - April 25 at 8:01 AM
Zymeworks (ZYME) Scheduled to Post Quarterly Earnings on ThursdayZymeworks (ZYME) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - April 25 at 2:32 AM
Zymeworks (NYSE:ZYME) Trading Up 3.5%Zymeworks (NYSE:ZYME) Trading Up 3.5%
americanbankingnews.com - April 21 at 3:12 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMESHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
prnewswire.com - April 20 at 12:15 PM
Zymeworks (NYSE:ZYME) Shares Up 3.5%Zymeworks (NYSE:ZYME) Shares Up 3.5%
marketbeat.com - April 19 at 12:24 PM
ATTENTION ZYME SHAREHOLDERS: Investors who Lost Money on Zymeworks Inc. are Urged to Contact Levi & Korsinsky about an Ongoing InvestigationATTENTION ZYME SHAREHOLDERS: Investors who Lost Money on Zymeworks Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
accesswire.com - April 19 at 7:35 AM
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamabs Promising DataBuy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
seekingalpha.com - April 18 at 6:22 PM
ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.
accesswire.com - April 18 at 7:30 AM
Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud AllegationsLevi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud Allegations
markets.businessinsider.com - April 16 at 6:55 PM
Maintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory HurdlesMaintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory Hurdles
markets.businessinsider.com - April 12 at 6:42 PM
Zymeworks Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zymeworks (ZYME)Zymeworks Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zymeworks (ZYME)
accesswire.com - April 12 at 10:05 AM
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYMELevi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
accesswire.com - April 12 at 10:00 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMESHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
prnewswire.com - April 12 at 9:30 AM
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYMEZymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
accesswire.com - April 12 at 7:30 AM
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
globenewswire.com - April 11 at 6:00 AM
Did Zymeworks Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZYMEDid Zymeworks Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZYME
accesswire.com - April 10 at 4:45 PM
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Heres Why a Trend Reversal May be Around the CornerZymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com - April 10 at 10:36 AM
Zymeworks (NYSE:ZYME) Trading Down 2.6%Zymeworks (NYSE:ZYME) Trading Down 2.6%
marketbeat.com - April 9 at 11:46 AM
Zymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ZYMEZymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ZYME
accesswire.com - April 8 at 4:00 PM
Opinion: The Next Generation of ADCs Will Improve Cancer TreatmentOpinion: The Next Generation of ADCs Will Improve Cancer Treatment
biospace.com - April 8 at 7:05 AM
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual MeetingZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
globenewswire.com - April 8 at 6:00 AM
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYMEZymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
accesswire.com - April 4 at 8:45 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMESHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
prnewswire.com - April 4 at 6:18 PM
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)
morningstar.com - April 4 at 7:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BELLUS Health logo

BELLUS Health

OTCMKTS:BLUSF
BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Dicerna Pharmaceuticals logo

Dicerna Pharmaceuticals

NASDAQ:DRNA
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Enanta Pharmaceuticals logo

Enanta Pharmaceuticals

NASDAQ:ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Turning Point Therapeutics logo

Turning Point Therapeutics

NASDAQ:TPTX
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Zymeworks logo

Zymeworks

NYSE:ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.